Germline genetic variants of the renin-angiotensin system, hypoxia and angiogenesis in non-small cell lung cancer progression : discovery and validation studies

cancers Article Germline Genetic Variants of the Renin-Angiotensin System, Hypoxia and Angiogenesis in Non-Small Cell Lung Cancer Progression: Discovery and Validation Studies Maria Joana Catarata 1,2,3,4,5,* , Rui Medeiros 4,5 , Maria JoséOliveira 1,2,4 , Alice Pêgo 3, João Gonçalo Frade 6, Maria Fátima Martins 6,7, Carlos Robalo Cordeiro 3,7, Felix J. F. Herth 8,9, Michael Thomas 9,10, Mark Kriegsmann 9,11 , Michael Meister 9,12, Marc A. Schneider 9,12 , Thomas Muley 9,12,†and Ricardo Ribeiro 1,2,6,13,† 1i3S-Institute for Research & Innovation in Health, University of Porto, 4200-135 Porto, Portugal; [email protected] (M.J.O.); ricardo.ribeir[email protected] (R.R.) 2INEB-Institute of Biomedical Engineering, University of Porto, 4200-135 Porto, Portugal 3Department of Pulmonology, Coimbra Hospital and University Center, 3000-075 Coimbra, Portugal; [email protected] (A.P.); crcordeir[email protected] (C.R.C.) 4Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal; [email protected] 5Molecular Oncology and Viral Pathology Group-Research Centre, Portuguese Institute of Oncology, 4200-072 Porto, Portugal 6Department of Clinical Pathology, Coimbra Hospital and University Center, 3000-075 Coimbra, Portugal; [email protected] (J.G.F.); [email protected] (M.F.M.) 7Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal 8Department of Pulmonology and Critical Care Medicine, Thoraxklinik, University of Heidelberg, 69126 Heidelberg, Germany; [email protected]g.de 9Translational Lung Research Centre (TLRC), member of the German Centre for Lung Research (DZL), 69120 Heidelberg, Germany; [email protected]g.de (M.T.); [email protected] (M.K.); [email protected]g.de (M.M.); [email protected]g.de (M.A.S.); [email protected]g.de (T.M.) 10 Department of Thoracic Oncology, Thoraxklinik, University of Heidelberg, 69126 Heidelberg, Germany 11 Institute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany 12 Translational Research Unit, Thoraxklinik, University of Heidelberg, 69126 Heidelberg, Germany 13 Laboratory of Genetics and Institute of Environmental Health, Faculty of Medicine, University of Lisbon, 1649-026 Lisboa, Portugal *Correspondence: [email protected]; Tel.: +351-22-607-4900 †These authors contributed equally to this paper. Received: 6 November 2020; Accepted: 14 December 2020; Published: 18 December 2020   Simple Summary: The presence of polymorphic gene variants in the human genome provides extensive genetic (and eventually phenotypic) variation affecting both normal physiological mechanisms and cancer pathogenesis. Functional genetic polymorphisms might have predictive and/or prognostic value in lung cancer, opening novel opportunities to improve prediction and guide clinical reasoning and therapeutics in lung cancer patients. Recent knowledge pinpoints a pleiotropic role for renin-angiotensin system, particularly in the lung and mainly through locally regulated alternative molecules and secondary pathways. Dysregulation of this system play a role in cell proliferation, hypoxia and angiogenesis, which processes are involved in lung cancer progression. Here we suggest that polymorphic variants in genes coding for renin-angiotensin system might play a role in Non-Small Cell Lung Cancer progression. Abstract: Introduction: The renin–angiotensin system (RAS) is involved in cell proliferation, immunoinflammatory response, hypoxia and angiogenesis, which are critical biological processes in Cancers 2020,12, 3834; doi:10.3390/cancers12123834 www.mdpi.com/journal/cancers Cancers 2020,12, 3834 2 of 16 lung cancer. Our aim was to study the association of putatively functional genetic polymorphisms in genes coding for proteins involved in RAS, hypoxia and angiogenesis with non-small cell lung cancer (NSCLC) prognosis. Methods: Genotyping of 52 germline variants from genes of the RAS and hypoxic/angiogenic factors/receptors was performed using MassARRAY iPLEX Gold in a retrospective cohort (n=167) of advanced NSCLC patients. Validation of the resulting genetic markers was conducted in an independent group (n=190), matched by clinicopathological characteristics. Results: Multivariate analysis on the discovery set revealed that MME rs701109 C carriers were protected from disease progression in comparison with homozygous T (hazard ratio (HR) =0.5, 95% confidence interval (CI) =0.2–0.8, p=0.010). Homozygous A and T genotypes for KDR rs1870377 were at increased risk for disease progression and death compared to heterozygous (HR =1.7, 95% CI =1.2–2.5, p=0.005 and HR =2.1, 95% CI =1.2–3.4, p=0.006, respectively). Carriers of homozygous genotypes for ACE2 rs908004 presented increased risk for disease progression, only in the subgroup of patients without tumour actionable driver mutations (HR =2.9, 95% CI =1.3–6.3, p=0.010). Importantly, the association of homozygous genotypes in MME rs701109 with risk for disease progression was confirmed after multivariate analysis in the validation set. Conclusion: This study provides evidence that MME polymorphism, which encodes neprilysin, may modulate progression-free survival in advanced NSCLC. Present genetic variation findings will foster basic, translational, and clinical research on their role in NSCLC. Keywords: genetic polymorphisms; lung cancer; renin–angiotensin; hypoxia; angiogenesis 1. Introduction Lung cancer is one of the most common malignancies worldwide and the most common cause of cancer death, with over one million people diagnosed worldwide each year [1]. The renin–angiotensin system (RAS) is an established primary regulator of blood pressure, homeostasis, and natriuresis [ 2 ]. Recent evidences indicate that angiotensin peptides might have a role in tumour cell proliferation, inflammation, immune surveillance, hypoxia and angiogenesis, which have been recognized as hallmarks of cancer, and thereby actively participating in lung tumour microenvironment regulation [ 3 , 4 ]. The enzymatic cascade leading to Angiotensin II (Ang II) production includes renin, which cleaves angiotensinogen (AGT) to form angiotensin I (Ang I). Angiotensin-converting enzyme (ACE) cleaves Ang I to produce Ang II [ 2 ]. The chymase, which might catalyse the conversion from Ang I to Ang II, has been associated with activation of proliferation, adhesion, regulation of E-cadherin expression, and modulation of the immunosuppressive microenvironment in lung carcinoma [ 5 , 6 ]. Angiotensin-(1-7) (Ang-(1-7)) has opposite effects to Ang II through binding to Mas receptor (MasR), and is obtained by catalysis from the enzymes ACE type 2 (ACE2) or neprilysin (NEP) [ 7 ]. On its turn, NEP has been associated with some malignancies, such as prostate, renal and lung cancer [8]. In vitro and in vivo studies showed that activation of the ACE/Ang II/angiotensin II type 1 receptor (ATR1) axis promotes cancer cell proliferation, invasion, angiogenesis and reduced immunosurveillance [ 9 – 11 ]. Conversely, anti-tumour effects were demonstrated for the ACE2/Ang-(1-7)/MasR axis [ 12 – 14 ]. Upregulated expression of ATR1 transcripts in lung tumours suggests that Ang II, acting upon the ATR1, plays an important role in cell growth and invasion [ 15 ], whereas decreased expression of genes encoding for ACE2/Ang-(1–7)/MasR axis proteins in lung tumours halt MasR signalling, which is contrary to Ang II/ATR1 [ 16 ]. Notably, clinical studies revealed that RAS inhibitors combined with chemotherapy and Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors prolonged progression-free survival in non-small cell lung cancer (NSCLC) patients [17–19]. Cancers 2020,12, 3834 3 of 16 Activity and modulation of the RAS are dependable of germline genetic variations [ 20 ], somatic mutations [ 21 ], environmental stimulus and from hypoxic lung tumour microenvironment [ 22 ]. Additionally, the RAS is causally and consequently associated with hypoxia and angiogenesis, considered in continuum as branches of RAS [ 4 ]. Notwithstanding, the RAS remains largely unexplored at translational and clinical levels in cancer, particularly NSCLC. In this study, we sought to evaluate whether functional genetic variants coding for proteins of RAS and hypoxic/angiogenic factors/receptors have predictive and/or prognostic value in NSCLC using progression-free survival (PFS) and overall survival (OS) as clinical endpoints. 2. Material and Methods 2.1. Study Population: Discovery and Validation Sets This study comprised a retrospective cohort of histologically confirmed NSCLC patients (n=167) with clinical advanced stage at diagnosis (IIIA-IVB), between 2012 and 2018. Participants were consecutively recruited during routine follow-up visit, since August 2017 to October 2018 from Coimbra University Hospital (discovery set). The validation set comprised an independent cohort of NSCLC patients (n=190) selected from the Lung Biobank Heidelberg, member of the Biomaterialbank Heidelberg (BMBH) and the biobank platform of the German Centre for Lung Research (DZL). All patients were recruited at Thoraxklinik (University Hospital of Heidelberg) between 2015–2018, using the same matched clinical and pathological criteria from the discovery set. Histolopathogical diagnoses in both sets were made by experienced pathologists following the 2009 and 2015 WHO classification criteria for lung cancer, accordingly to the year of patient’s diagnosis. The existence of concomitant primary tumours in another organ was considered as exclusion criteria for both cohorts. Clinical data was retrieved from clinical charts on pathological background, previous medication, Eastern Cooperative Oncology Group performance status (ECOG PS) at diagnosis, TNM staging according to 8th classification, tumour mutational status, type of cancer treatment, disease progression/death by clinical authors. Informed consent was obtained from each participant and all procedures are in agreement with Helsinki Declaration. In the discovery set, somatic mutations in EGFR,ALK and ROS1 were determined using fluorescence in situ hybridization (FISH), in patients with adenocarcinoma stage IVA-IVB, whereas for the validation set, somatic mutations were determined through panel-based next generation sequencing in advanced NSCLC patients [ 23 ]. In both cohorts, targeted therapies were administered to carriers of actionable driver mutations, whereas checkpoint inhibitors were used as second-, or third-line therapy for patients with PD-L1 expression on tumour cells below 50%. The primary endpoint was PFS and the time-to-disease progression was calculated in months, from the date of first line chemotherapy/target therapy, until the date of progression according to RECIST criteria. OS was included as secondary endpoint, and the time-to-death was computed in months from the date of first line chemotherapy/target therapy until the date of death/date of last visit. 2.2. Selection of Genetic Polymorphisms Fifty-two single nucleotide polymorphisms (SNP) included in the present study from the genes ACE,ACE2,AGT,AGTR1,AGTR2,MME,CMA1,MAS1,HIF1A,VEGFA,KDR,PGF and FLT1 (Table S1) were selected from search in genomic public databases, in silico analysis and review of scientific literature, to identify putatively functional polymorphisms [ 24 – 37 ]. Polymorphisms with minor allele frequency below 1% were excluded [37]. Cancers 2020,12, 3834 4 of 16 2.3. Genotyping 2.3.1. Discovery Set Each patient donated a sample of blood (~4 mL) for research, collected to EDTA-Vacutainer tubes, at the same time of blood collection for routine analytic follow-up. The collected blood was centrifuged to obtain the buffy coat, which was used to isolate and purify DNA by the EZ1 DNA Blood kit in the EZ1 BioRobot (QIAgen, Hilden, Germany). The selected SNPs were genotyped using the Sequenom Mass ARRAY matrix-assisted laser desorption/ionization time-of-flight mass spectrometry platform (Sequenom, San Diego, CA, USA). Primers were designed using semi-automated Assay Design 3.1 Software (Sequenom). The global genotyping success rate was 99.85% with 100% replication agreement among one third of the samples. 2.3.2. Validation Set Buffy coat samples were provided by Lung Biobank Heidelberg from patients diagnosed with advanced NSCLC (clinical stage IIIA-IVB). DNA extraction and purification were conducted using the FlexiGene DNA Kit (QIAgen). The resulting genetic polymorphisms, associated with disease progression or overall survival from multivariate analysis in the discovery set, were genotyped in the validation set using Real-Time PCR. Allelic discrimination was obtained using TaqMan SNP genotyping assays: ACE2 rs908004 (Assay ID: C___8816953_20), MME rs701109 (Assay ID: C____964850_10) and KDR rs1870377 (Assay ID: C__11895315_20) (all from Thermo Fisher Scientific, Waltham, MA, USA). Quality control included non-template controls in all runs and blind replicate assessment in 5% of the samples. Genotype was assigned for 96.3% of all samples tested. 2.4. Statistical Analysis Descriptives were depicted as average ± standard deviation or median (interquartile range) according to departure from normality (Shapiro-Wilk test). Central tendency data was compared using the t-test, Mann-Whitney or Kruskal-Wallis tests according to normality and stratification of independent variables. Categorical variables were expressed as frequency (percentage) and proportions tested using the chi-square test. The difference in median months of PFS and OS from both cohorts was calculated through Kaplan-Meier curve with log rank test. Four genetic models were considered in this study: each SNP was stratified according to the wild type allele into additive (“AA” genotype versus “Aa” versus “aa”), dominant (“AA” genotype versus “Aa” and “aa” genotypes), recessive (“Aa” and “AA” versus “aa” genotype) and heterosis (“Aa” versus “AA” and “aa” genotypes). The wild-type allele for each SNP was designated in agreement with Ensembl [ 37 ]. Empirical analyses were conducted on clinicopathological and genetic variables to test the association with time-to-outcome, using Cox regression analyses. After univariate analyses, p<0.10 and an effect >30% in hazard ratio (HR) were used as criteria for inclusion in a multivariated Cox with stepwise regression model. Genetic models with under-represented variant genotype (n<4) were excluded from the multivariate analysis, and only the genetic model with the highest likelihood ratio for each SNP was included in the multivariate model to avoid collinearity. The resulting multivariated model was further tested with bootstrapping (MonteCarlo simulations, 1000 iterations), to elect the resulting relevant markers to be tested in the validation set. To investigate the possible predictive value of each SNP in treatment response for first line therapy, and time-to-progression or time-to-death, exploratory analyses were conducted examining the effect of genotype in a subgroup of patients treated with first line platinum doublet chemotherapy and in another subgroup of wild-type EGFR (epidermal growth factor receptor) patients, using the same survival analysis methods. Sample size, power, effect size and number of events for survival analyses (assuming alpha =0.05 and power >0.8) were estimated in both cohorts. Statistical analyses were performed on STATA software version 16.0 (StataCorp, College Station, TX, USA). Cancers 2020,12, 3834 5 of 16 2.5. Ethics Approval This project has been reviewed and approved by Coimbra University Hospital’s Ethical Committee (ref. no. 0111/CES) and by the Portuguese National Committee for data protection (ref. no. 2588/2017). The biobank protocol of Lungbiobank Heidelberg was approved by the ethics committee of the University of Heidelberg (S-270/2001). 3. Results The clinicopathological characteristics of participating subjects from discovery and validation sets are described in Table 1. Regarding mutational status from discovery set (n=167), we observed that 10.8% of patients (n=18) had EGFR mutation (exon 19 deletions or exon 21 mutation), whereas 3.0% (n=5) had rearrangements in the gene encoding anaplastic lymphocyte kinase (ALK). Mutations of ROS1 were not detected. From the validation set (n=190), 15.3% (n=29) of NSCLC patients had EGFR mutation (exon 19 deletions or exon 21 mutation), 13.7% (n=26) were KRAS mutated, 4.2% (n=8) had EML4-ALK fusion, 2.6% (n=5) had BRAF V600E mutation. No other targetable mutations were identified. Concerning respiratory co-morbidities from discovery set, twenty patients (12.0%) had moderate-severe COPD with lung emphysema and one patient (0.6%) had sarcoidosis, whereas in the validation set there were fifty patients (26.3%) with moderate-severe COPD and lung emphysema, and five patients (2.6%) had idiopathic pulmonary fibrosis. Table 1. Patient0s clinical characteristics. Clinical Variables. Discovery Set (N=167) Validation Set (N=190) p Gender, n Males 123 (73.7%) 133 (70.0%) Females 44 (26.3%) 57 (30.0%) 0.445 * Age (years) Median (IQR) 64.0 (58.0–72.0) 65.0 (58.0–73.0) 0.773 ** Smoking Status, n(%) Never smokers 31 (27.7%) 20 (10.5%) Previously smokers 68 (60.7%) 97 (51.1%) Smokers 13 (11.6%) 73 (38.4%) <0.0001 * Hypertension, n(%) Yes 67 (48.6%) 91 (47.9%) No 71 (51.4%) 99 (52.1%) 0.911 * Anti-hypertension drugs, n(%) No 86 (65.2%) 126 (67.0%) iACE/ARB 46 (34.8%) 62 (33.0%) 0.728 * ECOG PS, n(%) 0–2 163 (97.6%) 188 (98.9%) >2 4 (2.4%) 2 (1.1%) 0.153 * Histology, n(%) Adenocarcinoma 116 (69.5%) 126 (66.3%) Squamous cell carcinoma 42 (25.1%) 62 (32.6%) Adeno +Squamous cell 9 (5.4%) 2 (1.1%) 0.066 * cTNM Stage, n(%) IIIA 20 (12.0%) 27 (14.2%) IIIB 32 (19.2%) 36 (18.9%) IIIC 21 (12.6%) 18 (9.5%) IVA 65 (38.9%) 66 (34.7%) IVB 29 (17.4%) 43 (22.6%) 0.597 * Treatment modality, n(%) Surgery +ChT 12 (7.2%) 0 (0.0%) ChT +RT 31 (18.6%) 81 (42.6%) Cancers 2020,12, 3834 6 of 16 Table 1. Cont. ChT 124 (74.3%) 109 (57.4%) <0.0001 * First-line treatment, n(%) Platinum based ChT 145 (86.8%) 155 (81.6%) TKI 22 (12.8%) 35 (18.4%) 0.194 * PFS (months) Median, 95% CI 7.5 (6.1–9.0) 8.1 (6.8–9.4) 0.415 *** OS (months) median, 95% CI 30.0 (16.9–43.2) 20.6 (16.3–24.9) 0.036 *** IQR—interquartil range; iACE—inhibitors of angiotensin-converting enzyme, ARB—AngiotensinII receptor blocker, ECOG PS—Eastern cooperative Oncology Group Performance Status; ChT—chemotherapy; RT—radiotherapy; TKI—tyrosine kinase inhibitors; 95% CI—confidence interval. PFS—progression-free survival, OS—overall survival. * Pearson Chi Square test. ** Mann-Whitney U test. *** Kaplan Meier curve with log rank test. The description of clinical-pathological variables is depicted in Table S2 with report of univariate analyses for PFS and OS. Genotypic distribution of functional SNPs in genes of the renin-angiotensin pathway, hypoxic and angiogenic factors using additive, dominant, recessive and heterosis models from discovery set are described in Table S3, together with hazard and survival univariate analyses. The univariate analysis showed that carriers of allele T (n=112, 67.1%) for the SNP rs4316 in ACE gene had a significant protection to disease progression (Hazard ratio (HR) =0.6, 95% confidence interval (CI) (0.4–0.9), p=0.011). Homozygous GG/CC for ACE2 rs908004 (n=151, 90.4%) had increased risk for disease progression (HR =2.1, 95% CI (1.1–3.9), p=0.021). Another SNP from MME gene that encodes for neprilysin, showed a tendency between the dominant genetic model of MME rs701109 and PFS, having the heterozygous CT and homozygous CC protection to disease progression (HR =0.6, 95% CI (0.3–1.0), p=0.064). Univariate analysis also showed a significant association between the functional genetic variant of VEGFA rs25648 with time to tumour progression, being the homozygous C and T (n=127, 78.9%) associated with worse prognosis (HR =1.7, 95% CI (1.1–2.6), p=0.030). The data showed a tendency between the heterosis genetic model of KDR rs1870377 and time to tumour progression, having the homozygous A and T increased risk to disease progression (HR =1.4, 95% CI (1.0–2.0), p=0.054) and to death (HR =1.7, 95% CI (1.0–2.7), p=0.034). Multivariate analysis included the relevant variables (both clinical-pathological and genetic) from univariate empirical analysis (Table 2, Table 3). The C carriers (n=149, 89.7%) for MME rs701109 had significantly decreased risk for disease progression than homozygotes T (n=17, 10.3%), regardless of relevant clinical-pathological variables, namely tumour size, distant metastasis, type of systemic therapy, treatment modality or from other relevant SNPs (Table 2). Homozygous A and T for KDR rs1870377 (n=99, 59.3%) had significantly lesser PFS and OS compared to heterozygous (n=68, 40.7%), regardless of relevant clinical and pathological variables (Tables 2and 3). Notably, these results maintained its significance after boostrapping, as a statistical method for internal validation. Cancers 2020,12, 3834 7 of 16 Table 2. Multivariate analysis for progression-free survival (PFS) in the discovery cohort (n=167). Variables PFS (Multivariate Stepwise Cox Proportional Hazards Model) Bootstrap HR (95% CI) pHR (95% CI) p T T1 Referent Referent T2 T3-4 1.7 (1.3–2.2) <0.0001 * 1.7 (1.3–2.3) <0.0001 * Distant metastasis No Referent Referent Yes 1.7 (1.2–2.4) 0.005 1.7 (1.1–2.5) 0.009 Type of Therapy Surgery +ChT Referent Referent ChT ChT +RT 1.5 (1.1–2.1) 0.012 * 1.5 (1.0–2.3) 0.053 * Type of Systemic Therapy, 1st line Platinum based ChT Referent Referent TKi 0.4 (0.2–0.8) 0.003 0.4 (0.2–0.7) 0.002 KDR rs1870377, Heterosis Model TA Referent Referent TT/AA 1.7 (1.2–2.5) 0.005 1.8 (1.2–7) 0.003 MME rs701109, Dominant Model TT Referent Referent TC/CC 0.5 (0.3–0.9) 0.018 0.5 (0.2–0.9) 0.030 Analyses were conducted using stepwise Cox regression, followed by Bootstrap analysis (Montecarlo simulations with 1000 iterations). HR, hazard ratio, 95% CI, confident interval, ChT, chemotherapy, RT, radiotherapy, TKi, tyrosine kinase inhibitors. * ptrend value. Table 3. Multivariate analysis of relevant variables for overall survival (OS) in the discovery set (n=167) using stepwise Cox regression, followed by Bootstrap analysis (Montecarlo simulations with 1000 iterations). Variables OS (Multivariate Stepwise Cox Proportional Hazards Model) Bootstrap HR (95% CI) pHR (95% CI) p T T1 Referent Referent T2 T3-4 1.5 (1.1–2.2) 0.018 * 1.5 (1.0–2.2) 0.066 * Distant metastasis No Referent Referent Yes 2.5 (1.5–4.3) 0.001 2.6 (1.5–4.5) 0.001 Age median ≤64.0 Referent Referent >64.0 1.7 (1.0–2.7) 0.031 1.6 (1.0–2.8) 0.069 KDR rs1870377, Heterosis Model TA Referent Referent TT/AA 2.1 (1.2–3.4) 0.006 2.0 (1.2–3.3) 0.012 HR, hazard ratio, 95% CI, confident interval. * ptrend value. Cancers 2020,12, 3834 8 of 16 Exploratory subgroup analyses were conducted among NSCLC patients from discovery set that included only patients under first line platinum-based doublet chemotherapy without actionable driver mutations (n=145) or EGFR wild-type (n=149). Within the MME (rs701109) and KDR (rs1870377) polymorphisms, we found evidence for an independent effect at PFS and OS respectively, across all subgroups. Notably, CT and CC patients for MME (rs701109) under first line platinum-based doublet chemotherapy or EGFR wild-type had protection for disease progression (HR =0.4, 95% CI (0.2–0.7), p=0.005 and HR =0.4, 95% CI (0.2–0.8), p=0.006, respectively). Homozygous A and T for KDR rs1870377 had increased risk to death also in patients under first line platinum doublet chemotherapy or EGFR wild-type (HR =1.9, 95% CI (1.1–3.2), p=0.019 and HR =2.0, 95% CI (1.2–3.4), p=0.011, respectively). Moreover, from the multivariate analysis conducted in the subgroup of patients treated with first line platinum-based doublet chemotherapy without actionable driver mutations (n=145), we also found that homozygous for ACE2 rs908004 had increased risk for disease progression, regardless of relevant clinical-pathological covariates (HR =2.9, 95% CI (1.3–6.3), p=0.010). The validation set included an independent matched cohort of NSCLC patients (Table 1) to validate the resulting genetic SNPs from the discovery set. Results from univariate analysis of clinicopathological variables in association with PFS and OS are described in Table S4. The genotype distribution and univariate analysis according to additive, dominant, recessive or heterosis models of MME rs701109, KDR rs1870377 and ACE2 rs908004 for hazard and survival analysis are depicted in Table S5. The genetic distribution of genotypes in MME rs701109, KDR rs1870377 and ACE2 rs908004 are similar among discovery and validation sets (p=0.204, p=0.846 and p=0.251, respectively) (Pearson Chi-square test). The multivariate model for PFS in the validation cohort is presented in Table 4. Homozygous (n=102, 53.9%) for MME rs701109 had significantly increased risk to disease progression compared to CT genotype (n=87, 46.0%), regardless of histology, type of systemic therapy or treatment modality (chemotherapy or chemo and radiotherapy). There was no significant effect on overall survival for MME rs701109, KDR rs1870377 and ACE2 rs908004. Table 4. Multivariate analysis of relevant variables for disease progression using stepwise Cox regression, followed by Bootstrap analysis with 1000 iterations from validation set (n=190). Variables PFS (Multivariate Stepwise Cox Proportional Hazards Model) Bootstrap HR (95%CI) pHR (95%CI) p Histology Adenocarcinoma Referent Referent Squamous cell 1.7 (1.2–2.4) 0.003 ** 1.7 (1.2–2.5) 0.003 ** Other * - - Type of Therapy ChT Referent Referent ChT +RT 0.4 (0.3–0.6) <0.0001 0.4 (0.3–0.6) <0.0001 Type of Systemic Therapy, 1st line Platinum based ChT Referent Referent TKi 0.4 (0.3–0.7) 0.001 0.4 (0.3–0.7) 0.002 MME rs701109, Heterosis Model TC Referent Referent TT/CC 1.6 (1.2–2.3) 0.005 1.6 (1.1–2.4) 0.007 PFS—progression-free survival, HR—hazard ratio, 95% CI—confident interval, ChT—chemotherapy, RT—radiotherapy, TKi—inhibitors of tyrosine kinase. * Adenocarcinoma+squamous cell. ** ptrend value. Cancers 2020,12, 3834 9 of 16 Subgroup analyses were also conducted in this set, for first line platinum-based doublet chemotherapy (n=155) and EGFR wild-type patients (n=161). The MME rs701109 polymorphism was associated with PFS only in the subgroup of patients with wild-type EGFR, being the homozygous at increased risk to disease progression (HR =1.7, 95% CI (1.1–2.5), p=0.009). 4. Discussion The work developed here sought to test the hypothesis that variants in genes coding for the renin–angiotensin system and for interacting hypoxia/angiogenesis key molecules might have predictive and prognostic value, respectively for NSCLC progression and survival. SNPs are the most common type of polymorphisms, accounting for 90% of genetic variations [ 38 ]. Nucleotide substitution, according to its location in germline DNA, may elicit functional modifications, ultimately at protein level, contributing to inter-individual variability, and correlating with relevant phenotypic alterations. The association between genetic polymorphisms and cancer susceptibility, progression, aggressiveness and death has been thoroughly described in the literature [38]. RAS was first discovered and related with the physiological regulation of systemic arterial pressure and involved in hypertension pathogenesis [ 39 ]. As a gatekeeper system, RAS is responsible for more than one function, including cell cycle regulation, inflammation, angiogenesis and fibrosis [ 3 ]. The capillary blood vessels in the lung are one of the major sites of ACE expression and Ang II production in the human body [ 40 ]. In fact, the increased ACE expression observed in several interstitial lung diseases supports pulmonary RAS and establishes a putative role for Ang II in the response to lung injury and fibrosis [ 4 ]. A previous report showed that the G-6A polymorphism of the AGT gene is associated with increased angiotensin production and idiopathic pulmonary fibrosis progression [ 41 ], which is associated with increased risk of lung cancer [ 42 ]. Furthermore, the insertion/deletion (I/D) polymorphism of ACE gene has been linked to the pathogenesis and progression of human cancers [ 43 , 44 ] and the lowest serum ACE levels were correlated with poorer prognosis and higher relapse rates in lung cancer [ 15 ]. We found that the association between ACE rs4316 genetic variant and PFS, despite being significant in univariate, the finding was not confirmed on multivariate analysis. It is an I/D polymorphism and is localized at intron 16 of ACE gene. This SNP has been associated with plasma ACE levels, with DD genotype carriers independently associated to higher expression [ 45 ], albeit no effect was noted on AngII [ 45 ]. Thus, it seems unlikely this SNP might impact the ACE/AngII/ATR1 axis, which has been associated with tumour cell growth and angiogenesis, partially justifying the absence of clinical impact in NSCLC patients with advanced stage disease. There are other possible reasons for the failure to replicate the prior findings. Many of the initial reports were present only in retrospectively defined subsets of the subjects studied and the main hypotheses investigated were related to cancer risk. Another possibility is that varied ethnic background of study populations may result in a different genetic background which confers a different biologic significance to a given functional polymorphism. ACE2 is responsible for converting AngII to Ang-(1-7), an agonist of Mas receptor (MasR). In a mouse lung xenograft model, it was previously shown that ACE2 overexpression inhibited both lung cancer cell proliferation In vitro and reduced tumour growth in vivo [ 46 ]. The ACE2 rs908004 is an intronic variant at the X-linked ACE2 gene [ 47 ]. Findings from the discovery cohort revealed that ACE2 rs908004 heterozygous carriers presented shorter time-to-progression, only in the subgroup of patients treated with first line platinum-based chemotherapy without actionable driver mutations. We hypothesize that heterozygous produces reduced levels of ACE2, contributing to the up-regulation of ACE/Ang II/AT1 receptor axis, or to linkage with another genomic region that might be relevant for this clinical phenotype. These hypotheses need to be confirmed in further studies. Furthermore, as with all gene association studies, subgroup analyses can lead to spurious associations and might justify our result. Nevertheless, there is lack of studies on genotype–phenotype relationship with this SNP in lung cancer, opening new opportunities for further investigations. Cancers 2020,12, 3834 16 of 16 66. Koukourakis, M.I.; Papazoglou, D.; Giatromanolaki, A.; Bougioukas, G.; Maltezos, E.; Sivridis, E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 2004,46, 293–298. [CrossRef] [PubMed] 67. Scartozzi, M.; Faloppi, L.; Svegliati-Baroni, G.; Loretelli, C.; Piscaglia, F.; Iavarone, M.; Toniutto, P.; Fava, G.; De Minicis, S.; Mandolesi, A.; et al. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study. Int. J. Cancer 2014,135, 1247–1256. [CrossRef] 68. Zhai, R.; Gong, M.N.; Zhou, W.; Thompson, T.B.; Kraft, P.; Su, L.; Christiani, D.C. Genotypes and haplotypes of the VEGF gene are associated with higher mortality and lower VEGF plasma levels in patients with ARDS. Thorax 2007,62, 718–722. [CrossRef] 69. Krippl, P.; Langsenlehner, U.; Renner, W.; Yazdani-Biuki, B.; Wolf, G.; Wascher, T.C.; Paulweber, B.; Haas, J.; Samonigg, H. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int. J. Cancer 2003,106, 468–471. [CrossRef] 70. Petrovic, M.G.; Korosec, P.; Kosnik, M.; Osredkar, J.; Hawlina, M.; Peterlin, B.; Petroviˇc, D. Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy. Mol. Vis. 2008,14, 1382–1387. 71. Glubb, D.M.; Cerri, E.; Giese, A.; Zhang, W.; Mirza, O.; Thompson, E.E.; Chen, P.; Das, S.; Jassem, J.; Rzyman, W.; et al. Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer. Clin. Cancer Res. 2011 ,17, 5257–5267. [CrossRef] 72. Keshavarz, L.; Yavarian, M. The association of Q472H variant in the KDR gene with recurrent pregnancy loss in Southern Iran: A case-control study. Int. J. Reprod. Biomed. 2019,17, 473–480. [CrossRef] 73. Meert, A.-P.; Paesmans, M.; Martin, B.; Delmotte, P.; Berghmans, T.; Verdebout, J.-M.; Lafitte, J.-J.; Mascaux, C.; Sculier, J.-P. The role of microvessel density on the survival of patients with lung cancer: A systematic review of the literature with meta-analysis. Br. J. Cancer 2002,87, 694–701. [CrossRef] 74. Trivella, M.; Pezzella, F.; Pastorino, U.; Harris, A.L.; Altman, D.G.; Prognosis In Lung Cancer Collaborative Study Group. Microvessel density as a prognostic factor in non-small-cell lung carcinoma: A meta-analysis of individual patient data. Lancet Oncol. 2007,8, 488–499. [CrossRef] Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).